Join
Live feed
·
PRReleasevia Quantisnow
Hepion Pharmaceuticals Inc. logo

Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

ByQuantisnow·Wall Street's wire, on your screen.
HEPA· Hepion Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HEPA (Hepion Pharmaceuticals Inc.) and more on Quantisnow.